Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix H. LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 81.00p 80.00p 82.00p 81.00p 81.00p 81.00p 11,206.00 07:37:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -1.4 1.8 46.3 63.62

Optibiotix H. (OPTI) Latest News

More Optibiotix H. News
Optibiotix H. Takeover Rumours

Optibiotix H. (OPTI) Share Charts

1 Year Optibiotix H. Chart

1 Year Optibiotix H. Chart

1 Month Optibiotix H. Chart

1 Month Optibiotix H. Chart

Intraday Optibiotix H. Chart

Intraday Optibiotix H. Chart

Optibiotix H. (OPTI) Discussions and Chat

Optibiotix H. Forums and Chat

Date Time Title Posts
23/3/201708:00OptiBiotix - The uncensored thread 1,042.00
22/3/201723:43OptiBiotix - Better Science, Better Health. Better buy some!21,026.00
06/3/201719:00Michaelmouse school of investing and fraud 19.00
16/2/201711:38Optibiotix (OPTI) wins investors as platforms expand10.00
23/8/201607:35Outlook2.00

Add a New Thread

Optibiotix H. (OPTI) Top Chat Posts

DateSubject
22/3/2017
08:20
Optibiotix H. Daily Update: Optibiotix H. is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix H. was 81p.
Optibiotix H. has a 4 week average price of 73.44p and a 12 week average price of 72.08p.
The 1 year high share price is 94p while the 1 year low share price is currently 0p.
There are currently 78,543,318 shares in issue and the average daily traded volume is 386,985 shares. The market capitalisation of Optibiotix H. is £62,441,937.81.
10/3/2017
13:01
neftanikoff: Be beneficial for the opti share price to have the name PROCTOR & GAMBLE actually mentioned in a RNS, even if there really has to be no detailed financial commitments, written at this stage. At least it would be a name that everyone knows instantly. For we could really do with getting over this 75p to 80p range and i am sure the mere mention of P & G in a RNS, would do the trick in clearing this obstacle.
24/2/2017
17:49
neftanikoff: Actually, i should think that soh is quite irked at the share price. At these few meetings i have been to, he has made a point of mentioning how the share price has consolidated around the 80p area (fallen back now, despite the ever increasing potential) and that it is way undervalued compared to the likes of DDDD. And did not some of his family go in at 75p some time ago (well according to 'you know who'), So although, he knows where opti is at and what is in store, i should think from the way he has spoken that he is peeved at the lack of movement in the share price. I should think many investors are surprised at the lack of major funds invested in opti. I should think that there must be some good news in the run up to the INVESTORS SHOW on 1st April, otherwise he may have a bit of a rough ride, the show is meant for these aim companies to do a selling job on pi's. Mind you, be nice when opti is big enough that it does not have to bother with shows like this. I do note that there is the usual DRAGONS DEN 10 minute slot where a spokesman from 5 companies presents ( sells) their company to 3 dragons, one being TW, who then decides on 1 of the 5 to invest in. Last year i remember TW saying he did not pick opti as he already had stacks of them, as it turned out, an investment in opti would have been a poor decision. This year, the opti DD is on at 13.07pm and is up against, METAL TIGER PLC, SAFRON ENERGY PLC, REACH4ENTERTAINMENT, WISHBONE GOLD PLC, i don't know anything about any of that lot.
24/2/2017
17:23
riskybusiness1: Finncap are awful and I hope they either improve or get dropped.Share price performance over the past 18months though not exciting has been pretty normal for a company grown so quickly in such a short period of time. Completely understand disappointment from those who followed the momentum expecting a quick gain in the 75-80p region. Tom winnifreth has not helped at all. If you think from sohs point of view he's grown a company from 8p up to 1£ currently consolidating between 60 & 80p 30 months in. Highly doubt he'll see share price as much of an issue. Many companies don't deliver a 50% share price rise in their lifetimes let alone 1200% peak within the first few years of listing. Primed for a while now for the next leg and will be down to commercial traction which should push us firmly past 1£. This doesn't happen overnight but have no doubt in the short term this is still a multibag opportunity. Long term, if the microbiome turns out to be the revolution in healthcare experts predict then opti will be massive. The early land grab will pay huge dividends. Even If opti were to be listed on Nasdaq today without skin your looking at minimum double the current valuation. Huge growing excitement around this area in the states. This must be in soh and the boards minds for the future
18/2/2017
15:09
riskybusiness1: Also dsm, two multi £bn multinational corporates on board already. Opti even has Gareth barker Vice President of dsm on board as non executive director. These two companies alone have the capability to blow share price out of the water.Shame anyone pays attention to the simple content on the other thread:'According to Stratistics MRC, the Global Human Microbiome Market is accounted for $130.23 million in 2015"Opti's share was? Oh that's right I think it was revenues of £80,000. Or was that this year?'The concept of opti as a whole was valued and listed at £5m in August 2014. Growing to £56m today. In this time the technology has been created and derisked with better than expected results.... He uses revenue figures as if opti have had products on the market for years and an experienced commercial team in place. Talking about revenues at this stage is a meaningless argument.He thinks go figure is the way opti intend to exploit slimbiome: 'If the USP for Go-Figure is Opti's "feel fuller for longer" then as soon as they license the technology to someone else then that USP for Go-Figure is lost and so are sales. By licensing to others they will just cannibalise their Go-Figure sales? and so it goes on.'Exemplifies his detachment from the business model. Go figure was created by chance earlier than expected to gain early market acceptance of slimbiome giving it to max to progress. Soh even mentions this was used as leverage in discussions between tata. The raising money point as elrico points out has been stated many times, opti is fully funded till profit. £3m in the bank £1.2m annual cash burn. Only cash raise will be for skin seeing as this part of the company was only purchased march last year and was not in the original opti plan. It is also an absolutely massive opportunity in it own right. If correct steps are taken over the years has been independently valued to reach a potential £250m piece of ip. Opt paid 700£k for 75%. I would expect at least £5-10m raise to start this journey.Once opti genuinely starts pushing go figure, slimbiome, lpldl, sweetbiotix, lpgos doubt it will take long to break even with the calibre of the newbies per and Christina. As well as the connections made through the partners currently in place with many more to be added. Huge demand for these scientifically backed products, market is growing fast. Right place right time.
17/2/2017
13:14
scotty1: Don't want to clutter the thread up wit rubbish so last post on the subject,until you come out with more predictions Diamond,here's a few there is more and as i said keep saying it and you will be correct one day ;) diamond fibre - 25 Jan 2017 - 10:00:09 - 19195 of 19867 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI Get ready, not long now, get ready to have your socks blown off. diamond fibre - 20 Jan 2017 - 17:37:08 - 19031 of 19867 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI Have a good weekend , let's see what Monday brings, I can smell that jam. DIAMOND. diamond fibre - 18 Jan 2017 - 15:26:48 - 18887 of 19867 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI My contact reckons Febuary is going to be a great month for us, he did mention the 5th of Feb but he said not to hold him to that date. diamond fibre - 10 Jan 2017 - 09:34:23 - 18531 of 19867 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI John, yes there are two deals going through due diligence, and big excitement in the skin development, looks like some news may have already leaked looking at the share price. diamond fibre - 20 Dec 2016 - 12:43:28 - 18061 of 19867 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI I promise you , meat on the bone coming soon. diamond fibre - 14 Dec 2016 - 16:03:13 - 17915 of 19867 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI Not privlieged to that info boys. But soon. diamond fibre - 21 Sep 2016 - 13:08:05 - 15710 of 19867 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI Just keep the faith, deals will be done very soon.
14/1/2017
09:37
parob: Indeed it's great to have you back Shrewdie! Was that your 100K at 70.75 or was it filled in smaller chunks? Just trying to work out if that's a new II buying... Looking forward to seeing finnCap's research note and target price when it's released. The very last research note was by Hybridan back in July: hTTp://www.shareprophets.com/file_download/807/OPTIHY2.pdf The target price at the time was 106p; since then there have been a number of developments, with the most significant IMO being the scientific 'breakthrough' where OPTI discovered microbiome modulators, novel oligosaccharides which increase the growth rate of bacteria already in the gut AND enhance a biological effect, for e.g growth of lp-ldl: "1. Demonstration in human gut models of the ability of its microbiome modulators to increase the growth rate of specific microbial species in the human microbiome. This has now been demonstrated in multiple species, including OptiBiotix's cholesterol reducing strain (LP-LDL (TM) ) 2. Demonstration in human gut models of the ability of its microbiome modulators to enhance a biological effect, such as cholesterol reduction. In the presence of microbiome modulators, OptiBiotix's cholesterol reducing strain (LP-LDL (TM) ) showed a threefold increase in cholesterol reduction OptiBiotix believes that this is the FIRST TIME that anyone has demonstrated a targeted change in the microbiome leading to an enhanced biological activity and improved health benefit (cholesterol reduction)." "OptiBiotix has demonstrated the ability of its novel oligosaccharides (carbohydrates that consist of a small number of sugars) to reduce cholesterol in human gut models by >20%." When they state 'more than 20%', is that an average figure across different groups? From the cholesterol results last April (before the breakthrough): -- 7.2% reduction in LDL cholesterol (bad cholesterol) averaged across the whole test group So does the 'more than 20%' relate to this group? What about this high cholesterol group (again these results are before the breakthrough): -- 36.7% reduction in volunteers' who had total cholesterol levels higher than 6mmol/L Could we be looking at a much higher reduction for those in this group, for example a 40%, 50%, 60%++ reduction? At this stage we've only been told it's more than 20%, but it could be much much higher - perhaps we'll find out once the scientific publications are published and/or when our cardiovascular products are launched. Would welcome anyone's thoughts on this. What kind of value will finnCap put on this breakthrough? It's a first! IMO once people have cottoned on to the trend reversal/chart we'll have plenty of money still sat on the sidelines piling in next week. Let's remember you can still buy in under 75p, the price SOH's brother paid in the Dec 2015 placing. Barchart is signalling a buy for the first time in months and months! hTTps://www.barchart.com/stocks/quotes/OPTI.LS/opinion I think I know which way the way the share price will be heading next week!
13/1/2017
18:07
neftanikoff: re 858, i wonder if you are autistic, only you take everything so literally, as share price say no tipster gets it right all of the time, with opti, they were in at 8 top sliced at 100 and are convinced it will breach 100 and more very soon, with all the expected good and positive news flow. The timing of news is difficult with complicated negotiations and dealing with MN'S who are not up to speed with the IP. You are right, 2016 was a poor year for opti share price wise but a good year in other ways. And what a great time for some, it has been since the rto. For TW, et all to speak so highly of the Management and opti and that the share the way they do, unlike other shares in their portfolio, speaks volumes to my mind. If anyone has met and listened to SOH, then your opinion of opti may well have changed. It must have been a disappointing week for you, after the rise in opti. You seem to take great glee in shares tipped by others when the share price goes down. There is a proper name for people like you, but i can't think of it right now, i can think of other names, but i am too polite to say them on a bb.
15/12/2016
17:07
elrico: Mazz - At the risk of being accused of bullying you...OPTI retaining 40% of Skinbiotix is a huge bonus. You fail to understand the mechanic of the demerger and what it means for OPTI, its shareholders and new shareholders in the new company. You may remember SOH stated Skinbiotix had been independently valued at c£250m, OPTI retain 40% of this potential value post demerger. In contrast, OPTI market value is c£50 million. Assuming Skinbiotix is a successful listing and the share price performs similarly to OPTI, we are in a win-win situation. Perhaps you will understand further when OPTI announce the Skinbiotix IPO price and then calculate your additional investment based on your OPTI holding and what skinbiotix is worth to OPTI as a company based on the 40% holding. Don't forget, OPTI PI's have a share in Skinbiotix and OPTI and possibly warrants and or discounted offering. You need to sit down and digest this, or go and seek professional advice before you do something rath and regret it.
13/12/2016
17:31
neftanikoff: allanrussell (post 17884), he (someuwin) may be a bit of a ramper, but his thoughts at that time 31/12/15, were my thoughts and i bet the thoughts of many others. He, i and others really thought that OPTI was to break its way throuigh the 100p barrier and on to much more. The share price at 31/12/15 was 90p. Although as soh has indicated, it has been a year of great signifcance concering the science and headway in probable jv deals, the share price has gone backwards, maybe it overreached (got ahead of) itself in 2015, after coming up from a mere 8p. Obviously the no real concrete monetised deal has not materialised. So things share price wise have not come up to scratch in 2016 and has left LTH and others who have bought in at the 65/85p level highly irritated/frustrated. So things have not worked out according to how shareholders would have liked, share price wise. These deals have taken longer to finalise that had been hoped for and we should perhaps had anticipated this, although soh did not help by being over exuberant in his excitement over the perceived expectations of the value in terms of OPTI m/c (maybe even he was caught out by the length of time it takes to cement a deal). BUT, imo, the aspirations of a much higher share price is still on the cards in 2017, as actual money making deals are finally made open via RNS deals and so those who are still here will eventually reap the benefits.
11/10/2016
10:25
parob: http://www.directorstalk.com/qa-stephen-ohara-chief-executive-officer-optibiotix-health-plc-lonopti-3/ Q&A with Stephen O'Hara Chief Executive Officer at Optibiotix Health PLC (LON:OPTI)Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O'Hara caught up with DirectorsTalk to discuss the new appointment of Martin Hunt as Chairman at SkinBiotics, how this fits into their strategy and what it means for shareholders Q1: Now Stephen, can you tell me more about the appointment of your new Chairman at the SkinBiotix division of Optibiotix Health?A1: Yes, sure. In July of this year Optibiotix announced a strategy to demerge and list as separate divisions and the appointment of the Chairman that we announced in the RNS is the start of this process. It's the process of demerging SkinBiotix and we think this is an important step in the development of SkinBiotics as we build a dedicated team, with dedicated leadership who have the expertise in the biotherapeutic space. I think investors have to realise that it's a very different space to the other Optibiotix divisions and requires specialised industry knowledge in cosmetics, medical devices and in pharmaceuticals and Martin's appointment is to start a process of building a dedicated team and a dedicated leadership with the industry knowledge and expertise to fully exploit the opportunities that we see in the microbiome space particularly in the skin microbiome space. Q2: So what could this mean for Optibiotix's investor and how will it fit into your overall strategy?A2: Well our strategy is to build value for shareholders as part of that process, we're looking to build each division to a point where we can demerge then list it separately, if you look at SkinBiotix and look at the area that it works in, we don't believe that the market really recognises the value within SkinBiotix, let me give you a couple of examples. The first example is the size of the market opportunity in skin so these market opportunities include cosmetic skin care, a market of $121 billion, healthcare-acquired infections, a market of $82 billion, dermatology, and $10 billion on wound care. I guess the other aspect is that if you look at the other ways in terms of value in a company over the market opportunities that it's targeting is the value of comparison so SkinBiotix is in the biotherapeutic space and if you could comparate a company such a 4D Pharma their valuations tend to be in the hundreds of millions rather than the tens of millions and we think that with SkinBiotix the true value of the division within Optibiotix is not being fully realised. By taking it out of Optibiotix and putting it into a separate company, which is demerge Optibiotix and then list it separately will best realise value for shareholders and there's other examples of this that have set a precedent for this type of approach and they include Racal who spun off Vodafone and Chubb and more recently Paypal from Ebay. What it means in terms of shareholders is typically they retain their position in Optibiotix but they also gain a proportional position in the new listed company so from a shareholder point of view it's a way of greatly increasing the value of their shareholding. Q3: With that in mind then, when do you think we can expect any listing to happen?A3: We can't give the exact details of when the listing will happen but this is part of the process of looking to list SkinBiotix separately, timing will be market sensitive and we will announce an RNS on that nearer the time. We look at market conditions over the forthcoming months, we look at putting the team in place and getting the right people who we feel can lead a team and who have the expertise to fully exploit the opportunity, once we have those in place we will produce an RNS, we will signal our intent then in terms of a listing. We see this as not a longer term opportunity, we see this, dependant on market conditions, as a short to medium term opportunity and we're pressing ahead on that as I indicated in the earlier question and the first part of that process was appointing a Chairman. So we're really excited by the opportunity and we think it's a great way to build shareholder value, we think if we get it right and we take it to the market then very much like as we did with OptiBiotix we were able to get a great increase in share price and value over a short period of time. We think that SkinBiotix opportunity is very similar; big markets, big opportunities and as I said earlier comparator companies with high market valuations, I think it's a great opportunity here for investors in Optibiotix Health.
Optibiotix H. share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170323 08:22:45